Topical Oncokinase Inhibitor Compositions for Epidermal Hyperplasia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for congenital epidermal and dermal hyperplasia, such as Costello syndrome and nevus sebaceous syndrome, as well as vascular anomalies like port-wine stains and malformations, lack effective topical compositions that can inhibit oncokinases associated with the RAS/RAF/MEK/ERK signaling cascade.
Innovation Solution
Topical compositions containing oncokinase inhibitors, solubility enhancers, and bases are developed, which include trametinib and other kinase inhibitors, solubility enhancers like ethyl acetate, and bases like white petrolatum, applied to the skin to treat hyperplasia and vascular anomalies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for congenital epidermal and dermal hyperplasia, then the treatment approach is simple, but the therapeutic effectiveness is insufficient
Solution Approach 1:
The patent creates a composite topical composition integrating multiple functional components: oncokinase inhibitor (trametinib) as active pharmaceutical ingredient, solubility enhancer (ethyl acetate) to improve drug dissolution, and base (white petrolatum) for topical delivery. This composite formulation resolves the contradiction by combining simplicity of topical application with enhanced therapeutic effectiveness through optimized drug delivery system.
Solution Approach 2:
The patent modifies the physical-chemical parameters of the drug formulation by introducing ethyl acetate as a solubility enhancer, which changes the dissolution characteristics of trametinib. This parameter change improves the bioavailability and therapeutic effectiveness of the oncokinase inhibitor while maintaining a relatively simple topical composition structure.
2Reliability
If oncokinase inhibitors are incorporated into topical compositions, then therapeutic effectiveness improves, but formulation complexity increases
Solution Approach 1:
The patent employs ethyl acetate as an intermediary substance that facilitates the incorporation of oncokinase inhibitor into the topical formulation. This solubility enhancer acts as a mediator between the hydrophobic trametinib molecule and the aqueous-based petrolatum vehicle, enabling effective drug delivery without significantly complicating the manufacturing process.
Solution Approach 2:
The patent applies local quality enhancement by concentrating the oncokinase inhibitor and solubility enhancer in the topical formulation specifically at the site of hyperplastic tissue. This localized high-concentration delivery maximizes therapeutic effectiveness at the target site while keeping the overall formulation relatively simple for manufacturing.
3Reliability
If trametinib is used to inhibit kinases in RAS/RAF/MEK/ERK signaling cascade, then hyperplasia and discoloration are reduced, but the treatment requires complex biochemical pathway targeting
Solution Approach 1:
The patent extracts and targets the specific oncokinase enzyme (MEK) within the complex RAS/RAF/MEK/ERK signaling cascade. By using trametinib to selectively inhibit MEK, the treatment isolates and addresses the critical pathological node in the signaling pathway, achieving therapeutic benefit by focusing on one key enzyme rather than attempting to modulate the entire complex cascade.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively reduce hyperplasia, discoloration, and symptoms associated with congenital skin conditions by inhibiting kinases, providing therapeutic benefits for conditions like Costello syndrome and port-wine stains.
Implementation Method 1
The solubility enhancer of such embodiments may be ethyl acetate, ethanol, methanol, dimethylformamide (DMF), acetone, acetonitrile, tetrahydrofuran (THE), acetic acid, dimethyl sulfoxide (DMSO), chloroform, and the like and combinations thereof
Data Source
AI summary
Compositions and methods for treating congenital epidermal or dermal hyperplasia by using topically administered oncokinase inhibitors such as trametinib, pyrrole derivatives, TAK-733, CH4987655, RDEA119/BAY 869766, cobimetinib, binimetinib, selumetinib, and the like are described herein.